Mirror Biologics, Inc. is a clinical-stage, international biopharmaceutical company pioneering the development and manufacturing of the next generation of immunomodulatory vaccines and immunotherapy treatments where the active ingredients include living immune cells. Our novel Mirror Effect® technology platform and products are protected by over 200 issued patents worldwide. The Mirror Effect® technology platform broadly addresses unmet medical needs for the treatment and prevention of cancers, infectious diseases and the medical problems associated with the weakening or senescence of the immune system as we age. Our lead products are now entering late stage clinical development and we are preparing the infrastructure necessary for commercialization.
Immunotherapy of cancer, also called immuno-oncology, is a form of cancer treatment that is designed to harness the power of the body’s own immune system to control and eliminate cancer. Current immunotherapy technologies, such as checkpoint inhibitor drugs and CAR-T cell therapies have limitations as to the types of cancers they are able to treat and the percentage of patients with these susceptible types of cancer that actually respond. Besides limited applicability and efficacy, these first generation checkpoint inhibitor and CAR-T immunotherapies are expensive and can cause serious side-effects. Our next generation Mirror Effect® technology provides solutions to these problems, broaden the indications that can respond to immunotherapy, significantly lower the cost and significantly reduce the side-effects.
AlloStim® cells are patented immune cells developed with Mirror Effect® technology. These novel cells are differentiated and expanded in specialized “artificial lymph node” bioreactors from precursor cells purified from the blood of healthy donors. One donor can produce sufficient AlloStim® cells to treat hundreds of patients, providing an unprecedented economy of scale. AlloStim® cells do not directly kill tumors or viral-infected cells, they are actually rejected and eliminated by the host immune system shortly after being administered. The rejection of AlloStim® is designed to cause beneficial changes in the immune system which permit the host immune system to become educated and to overcome tumor and viral immune avoidance and immune suppression strategies, leading to immune control and elimination of existing tumors and viral infected cells.
Our Mirror Effect® technology platform enables us to reverse engineer select components of immune cascades proven to be effective, while excluding any associated toxicities. The safe components of the cascades are then imprinted upon patients in a manner such as to dominate over failed resident immune responses. Our Mirror Effect® technology platform provides unprecedented capability to re-program immune responses that can be directed to treat or prevent cancer and viral pathogens, as well to remodel immune systems of the elderly to assure high quality of life as we age.
Our current research programs are focused on development of:
A therapeutic immunomodulatory treatment for chemotherapy-refractory metastatic solid tumors. Our lead cancer treatment programs target metastatic colorectal cancer (USA) and advanced/metastatic liver cancer (Asia).
A “pan-viral” vaccine to prevent elderly adults from any type of respiratory viral infection, including COVID-19, influenza and any future novel virus that might emerge.
An immunomodulatory vaccine to prevent or slow down the weakening of the immune system as we age.
A cloud-based centralized control over portable manufacturing pods, including an automated, closed, sterile “plug-and-play” cell processing system, an “artificial lymph node” high density bioreactor and horizontally-integrated supply chain of reagents, disposables and media formulations, for the economical, large-scale commercial manufacturing, formulation and distribution of living cell products.